

UNITED STATES HOUSE OF REPRESENTATIVES
2017 FINANCIAL DISCLOSURE STATEMENT

Form A
For Use by Members, Officers, and Employees

HAND
DELIVERED

Page 1 of 32

Name: Bill Elens

Daytime Telephone: 202.225-6101

18 JUN 19

PH 3:12 (Office Use Only)

MD

A \$200 penalty shall be assessed against any individual who files more than 30 days late.

FILER STATUS	<input checked="" type="checkbox"/> Member of the U.S. House of Representatives	State: <u>TX</u> District: <u>15</u>	<input type="checkbox"/> Officer or Employee	Employing Office: _____	Staff Filer Type: (If Applicable) <input type="checkbox"/> Shared <input type="checkbox"/> Principal Assistant
REPORT TYPE	<input type="checkbox"/> 2017 Annual (Due: May 15, 2018)	<input checked="" type="checkbox"/> Amendment	<input type="checkbox"/> Termination	Date of Termination: _____	

PRELIMINARY INFORMATION - ANSWER EACH OF THESE QUESTIONS

A. Did you, your spouse, or your dependent child: a. Own any reportable asset that was worth more than \$1,000 at the end of the reporting period? or b. Receive more than \$200 in unearned income from any reportable asset during the reporting period?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	F. Did you have any reportable agreement or arrangement with an outside entity during the reporting period or in the current calendar year up through the date of filing?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
B. Did you, your spouse, or your dependent child purchase, sell, or exchange any securities or reportable real estate in a transaction exceeding \$1,000 during the reporting period?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	G. Did you, your spouse, or your dependent child receive any reportable gift(s) totaling more than \$390 in value from a single source during the reporting period?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
C. Did you or your spouse have "earned" income (e.g., salaries, honoraria, or pension/IRA distributions) of \$200 or more during the reporting period?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	H. Did you, your spouse, or your dependent child receive any reportable travel or reimbursements for travel totaling more than \$390 in value from a single source during the reporting period?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
D. Did you, your spouse, or your dependent child have any reportable liability (more than \$10,000) at any point during the reporting period?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	I. Did any individual or organization make a donation to charity in lieu of paying you for a speech, appearance, or article during the reporting period?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
E. Did you hold any reportable positions during the reporting period or in the current calendar year up through the date of filing?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	ATTACH THE CORRESPONDING SCHEDULE IF YOU ANSWER "YES"	

IPO AND EXCLUSION OF SPOUSE, DEPENDENT, OR TRUST INFORMATION - ANSWER EACH OF THESE QUESTIONS

IPO - Did you purchase any shares that were allocated as a part of an Initial Public Offering during the reporting period? If you answered "yes" to this question, please contact the Committee on Ethics for further guidance.	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
TRUSTS - Details regarding "Qualified Blind Trusts" approved by the Committee on Ethics and certain other "excepted trusts" need not be disclosed. Have you excluded from this report details of such a trust that benefits you, your spouse, or dependent child?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
EXEMPTION - Have you excluded from this report any other assets, "unearned" income, transactions, or liabilities of a spouse or your dependent child because they meet all three tests for exemption? Do not answer "yes" unless you have first consulted with the Committee on Ethics.	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>

This amendment includes replacement pages for Exhibit A (Pages 27 and 28) which were not available at the time of original report filing.

Exhibit A (1x2)

SANDERS OPPORTUNITY FUND (INSTITUTIONAL), L.P.

Schedule of Investments

December 31, 2017

Description	Shares	Cost	Estimated Fair Value	% of Total Net Assets
Restricted Common and Preferred Stock:				
<u>Marketing</u>				
Big Tent Entertainment, LLC (1)				0.00%
Total Restricted Common and Preferred Stock				0.00%
 Limited Partnerships				
<u>Investment</u>				
Corporate Opportunities Fund (Institutional), L.P. (2)				
Life Sciences Opportunities Fund II, L.P. (2)				
Life Sciences Opportunity Fund, L.P. (2)				
SMH Private Equity Group II, L.P. (2)				33.91%
<u>Pharmaceuticals</u>				
SMH Spepharm II, LLC (2)				
SMH Spepharm, LLC (2)				
SMH Swiss Pharma II, LLC (2)				
SMH Swiss Pharma, LLC (2)				24.10%
<u>Healthcare</u>				
SMH NuPhysicia, LLC (2)				
SMH NuPhysicia, LLC Series C (2)				2.32%
<u>Software</u>				
SMH Quodd, LLC (2)				
SMH Quodd II, LLC (2)				
SMH Zilliant LLC Preferred Series B (2)				
SMH Zilliant LLC Preferred Series C (2)				36.83%
Total Investment in Limited Partnerships				97.16%

The accompanying notes are an integral part of this statement.

SANDERS OPPORTUNITY FUND (INSTITUTIONAL), L.P.

Schedule of Investments (Continued)

December 31, 2017

Description	Shares	Cost	Estimated Fair Value	% of Total Net Assets
<u>Warrants</u>				
<u>Investment</u>				
Life Sciences Opportunities Fund, L.P. (2)				
Life Sciences Opportunities Fund, Inst'l L.P. (2)				
SMH Private Equity Group II, L.P. (2)				0.00%
Total Warrants				0.00%
Total Investments in Portfolio Companies				97.16%
Net unrealized loss on investments				

NOTE: Investments are in entities with primary operations in the United States unless otherwise noted.

(1) Securities are restricted against transfer unless the transfer is affected in compliance with the Securities Act of 1933, as amended and applicable state securities laws.

(2) This company is an affiliate of the Partnership.

The accompanying notes are an integral part of this statement.

28

Exhibit A(2x2)